## TROW: T. Rowe Price Group, Inc. - XLF: Financial Services

### Executive Summary

No thesis match: MRS_10 -0.9% below STRENGTH zone (3.0-6.0%); PEG 4.83 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.9% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($100.03)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. T. Rowe Price Group (Nasdaq:TROW) - Stock Analysis**
- Source: Simply Wall Street | 20251221T100828 | Neutral | Relevance: 100%
- T. Rowe Price Group (TROW) is an investment manager trading below its estimated fair value. The company is driving asset growth through innovation in retirement and ETF products, global expansion, and investments in technology to improve efficiency and profitability. Despite risks like fee compression and outflows, strategic moves into ETFs and alternative investments are expected to boost assets under management and revenue.

**2. Confluence Investment Management LLC Buys 25,316 Shares of T. Rowe Price Group, Inc. $TROW**
- Source: MarketBeat | 20251223T102637 | Neutral | Relevance: 100%
- Confluence Investment Management LLC increased its stake in T. Rowe Price Group by 2.7%, acquiring an additional 25,316 shares to hold a total of 973,769 shares valued at approximately $99.95 million. T. Rowe Price (NASDAQ:TROW) recently declared a quarterly dividend of $1.27 per share and exceeded Q3 earnings estimates, though analysts maintain a cautious "Reduce" rating with an average target price of $108.31. Over 73% of the stock is owned by hedge funds and institutional investors, while a VP recently sold 4,260 shares.

**3. Bubbles, barbells, and inflation risk: November 2025 remix**
- Source: T. Rowe Price | 20251222T220903 | Neutral | Relevance: 100%
- T. Rowe Price's Asset Allocation Committee is maintaining a neutral risk posture while adjusting its allocation mix, specifically by shifting capital from core large-cap equities into a barbell of U.S. value and U.S. growth with a modest tilt towards small-cap growth. The committee is positioned for broader equity market performance and favors inflation-linked bonds due to upside risks to inflation, despite strong S&P 500 earnings and AI spending. However, concerns about high market concentration, crowded risk assets, and high-quality U.S. large-cap valuations are significant factors influencing their strategy.

**4. Historyâ€™s edge: Why Niall Ferguson wants us to take the long view**
- Source: T. Rowe Price | 20251223T160829 | Somewhat-Bullish | Relevance: 100%
- Sir Niall Ferguson emphasizes the importance of historical perspective in financial markets, arguing that understanding the past helps identify market shifts and risks, which short-term data models often miss. He highlights that currency and bond markets are crucial indicators of regime changes, often signaling transitions before equity markets. Ferguson also discusses the relative positions of the U.S. and China, suggesting that despite U.S. challenges, China's issues are greater, and American business strength provides significant resilience.

**5. T. Rowe (TROW) Price Sees Modest Target Increase as Near-Term Pressures Persist**
- Source: Insider Monkey | 20251223T172800 | Neutral | Relevance: 97%
- Morgan Stanley recently raised its price target for T. Rowe Price Group, Inc. (TROW) to $128 from $126, while maintaining an Equal Weight rating, citing weaker-than-expected client flows in Q4. Additionally, T. Rowe Price and Goldman Sachs Asset Management launched co-branded model portfolios aimed at mass-affluent and high-net-worth clients, a strategic move following their alliance in September. Despite these developments, the article suggests that near-term pressures persist for TROW.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Keefe, Bruyette | $115 | $117 | -2% |
| 2025-12-17 | Morgan Stanley | $128 | $126 | +2% |
| 2025-12-12 | Barclays | $102 | $101 | +1% |
| 2025-12-05 | Evercore ISI Gr | $115 | $118 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Keefe, Bruyette | main | Market Perform |
| 2025-12-17 | Morgan Stanley | main | Equal-Weight |
| 2025-12-12 | Barclays | main | Underweight |
| 2025-12-05 | Evercore ISI Gr | main | In-Line |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 19 ($0.32M) |
| Sells | 14 ($7.63M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.1% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 8 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-0.1%)
- Blackrock Inc.: 9.4% (-1.6%)
- State Street Corpora: 6.5% (-2.7%)
- Charles Schwab Inves: 3.6% (+1.1%)
- Geode Capital Manage: 2.8% (+1.0%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.9% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $7.6M in recent transactions.
3. Valuation stretched: PEG 4.8x requires aggressive growth execution.
4. Elevated short interest (8.8%): bears positioning against stock.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.83 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROA 10%, margin 29%). Balance sheet: strong liquidity (11.4x), low leverage (D/E 0.26). Insider selling cluster ($7.6M in 90 days), potential headwind. Institutional flow bearish (8 selling vs 2 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $22.9B |
| Beta | 1.54 |
| 52W Range | $77.85 - $118.32 |
| Short Interest | 8.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.83 |
| Forward P/E | 10.1 |
| Current P/E | 10.7 |
| YoY Growth | 5.9% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from 3.0% to -0.9% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.9pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 52. OFD pattern: -MUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.93% (CS: 52) | Neutral |
| RSI_14 | 52.3 | Neutral |
| MACD Histogram | -0.03 | Bearish |
| vs SMA20 | 1.002x | Above |
| vs SMA50 | 1.010x | Above |
| vs SMA200 | 1.045x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $104.03
- **Stop Loss:** $100.03 (3.8% risk)
- **Target:** $108.03 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 224
- **Position Value:** $23,302.72
- **Portfolio %:** 23.30%
- **Risk Dollars:** $900.00
- **Risk Per Trade:** 0.90%
- **Modifiers:** L1 120% | L2 75% | Combined 0.90x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-06 (Est: $2.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.54 | $2.81 | +10.5% |
| 2025Q2 | $2.13 | $2.24 | +4.9% |
| 2025Q1 | $2.13 | $2.23 | +4.7% |
| 2024Q4 | $2.21 | $2.12 | -4.1% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*